Related references
Note: Only part of the references are listed.Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence
Peter S. Hall et al.
PHARMACOECONOMICS (2011)
Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature
Stella Mook et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Health economics in drug development: Efficient research to inform healthcare funding decisions
Peter S. Hall et al.
EUROPEAN JOURNAL OF CANCER (2010)
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
Paula K. Lorgelly et al.
EUROPEAN JOURNAL OF HEART FAILURE (2010)
Researchers Consider Value-of-Information Theory for Selecting Trials
Charlie Schmidt
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer
Takeru Shiroiwa et al.
MOLECULAR DIAGNOSIS & THERAPY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
Daphne T. Tsoi et al.
ONCOLOGIST (2010)
Mammostrat (R) as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
John M. S. Bartlett et al.
BREAST CANCER RESEARCH (2010)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
Nicole Mittmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
Kathy S. Albain et al.
LANCET (2009)
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan
Masahide Kondo et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
Mary C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis
J. Karnon et al.
BRITISH JOURNAL OF CANCER (2007)
Health related quality of life in different states of breast cancer
Mathias Lidgren et al.
QUALITY OF LIFE RESEARCH (2007)
Trastuzumab treatment and the risk of central nervous system (CNS) metastases
M. C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Polychemotherapy for early breast cancer: Results from the international adjuvant breast cancer chemotherapy randomized trial
[Anonymous]
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies
Gary H. Lyman et al.
CANCER (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Handling uncertainty in cost-effectiveness models
AH Briggs
PHARMACOECONOMICS (2000)
Survival of patients with a new diagnosis of heart failure: a population based study
MR Cowie et al.
HEART (2000)
Share Paper
